PROJECT I - IMMUNE BARRIERS TO AAV GENE THERAPYThe performance of novel AAV serotypes, with the use of the self complementing genome, has vastlyimproved the prospects of successful liver-directed in vivo gene therapy. Despite these encouraging data, anumber of potential barriers remain, primarily focused on the immunologic biology of in vivo gene therapy.This project will systemically address the immunologic response to in vivo gene therapy of novel AAVs as aprerequisite to their considerations in clinical applications. The first specific aim will focus on the identificationof a clinical candidate which is defined as the actual vector to be considered in the Phase 1 clinical trial. Thetwo components of the vector that will be extensively studied and optimized are: 1) the capsid, evaluated forefficiency and stability of gene transfer, toxicity, transgene and capsid T cells, pre-existing immunity andbiodistribution; and 2) the genome, evaluated for peak and onset of expression. The second specific aim willanalyze the role of pre-existing T cells to AAV capsids in terms of the safety and efficacy of liver-directedgene transfer. The third specific aim will evaluate the role of the target organ in eliciting problematicimmunologic responses, specifically focusing on activation of innate immunity or inflammation. Thesestudies will focus on murine systems in establishing basic principles which are followed up selectively innonhuman primates. The project will extensively use the Vector and Morphology Cores and will collaboratedirectly with Project II on the evaluation of vector efficacy in the OTC-deficient mouse model and with ProjectIII by providing NHP tissue for molecular characterization.Lay description. A vector of use for the treatment of OTC deficiency called the clinical candidate will becreated. Potential immunologic responses of the recipient to the vector will be studied.
Showing the most recent 10 out of 26 publications
